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Objectives We appraised the incidence and clinical outcomes of patients who were treated with the valve-in-valve (ViV)
technique for hemodynamically destabilizing paraprosthetic leak (PPL).
Background Device malpositioning causing severe PPL after transcatheter aortic valve implantation is not an uncommon finding.
It occurs after release of the prosthesis, leading to hemodynamic compromise. It can be managed successfully in
selected cases with implantation of a second device inside the malpositioned primary prosthesis (ViV technique).
Methods Consecutive patients (n  663) who underwent transcatheter aortic valve implantation with the 18-F CoreValve
ReValving System (Medtronic, Inc., Minneapolis, Minnesota) at 14 centers across Italy were included in this pro-
spective web-based registry. We identified patients treated with the ViV technique for severe PPL and analyzed
their clinical and echocardiographic outcomes. Primary end points were major adverse cerebrovascular and car-
diac events and prosthesis performance at the 30-day and midterm follow-up.
Results Overall procedural success was obtained in 650 patients (98.0%). The ViV technique was used in 24 (3.6%) of
663 patients. The 30-day major adverse cerebrovascular and cardiac event rates were 7.0% and 0% in patients
undergoing the standard procedure and ViV technique, respectively (p  0.185); the mortality rates were 5.6%
versus 0% in patients undergoing the standard procedure and ViV technique, respectively (p  0.238). There was
an improvement in the mean transaortic gradient in all patients without significant difference between the 2
groups (from 52.1  17.1 mm Hg and 45.4  14.8 mm Hg [p  0.060] to 10.1  4.2 mm Hg and 10.5  5.2
mm Hg, respectively [p  0.838]). At 12 months, the major adverse cerebrovascular and cardiac event rates in
the standard procedure and ViV technique groups were 4.5% and 14.1%, respectively (p  0.158), and the mor-
tality rates were 4.5% versus 13.7%, respectively (p  0.230).
Conclusions This large, multicenter registry provides important information about the feasibility, safety, and efficacy of the
ViV technique with the third-generation CoreValve ReValving System. The clinical and echocardiographic end
points compare favorably with those of patients undergoing the standard procedure. The ViV technique offers a
viable therapeutic option in patients with acute significant PPL without recourse to emergent surgery. (J Am
Coll Cardiol 2011;57:1062–8) © 2011 by the American College of Cardiology Foundation
Published by Elsevier Inc. doi:10.1016/j.jacc.2010.11.019Transcatheter aortic valve implantation (TAVI) has matured
into a viable treatment alternative for patients with severe aortic
stenosis at high-risk for conventional aortic valve replacement
(1,2). Large registries have indicated that TAVI can be
accomplished successfully with acute and midterm clinical
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TAVI is technically a challenging procedure even for
experienced operators. A careful assessment of the anatomic
features of the aortic apparatus is an integral part of the
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March 1, 2011:1062–8 Valve-in-Valve for Aortic Bioprosthesis Malpositionprocedure (3). Accurate positioning of the device with respect
o the aortic annulus is critical for ensuring a successful
rocedure, whereas suboptimal deployment can result in sig-
ificant hemodynamic compromise that is poorly tolerated and
ortends a poor procedural and clinical outcome.
It is almost impossible to reposition fully the current
ommercially available devices after initial deployment.
everal percutaneous techniques have been described to
anage suboptimal prosthesis deployment without recourse
o surgical bailout therapy (4,5).
Paraprosthetic leak (PPL) is a common finding after device
eployment (1,2). It is usually mild and well tolerated (1,2).
arely, it is severe and induces hemodynamic instability (1,2).
he mechanism of PPL in cases of suboptimal deployment of
he CoreValve ReValving System (CRS) (Medtronic, Inc.,
inneapolis, Minnesota) already has been described (4).
oreover, the feasibility of implanting a second prosthesis
nside the first malfunctioning CRS device with the valve-in-
alve (ViV) technique has been reported (4,5).
In the present multicenter prospective study, including a
ohort of patients undergoing TAVI with the 18-F CRS
evice, we analyzed the incidence and characteristics of PPL
equiring a second device with the ViV technique and report
linical and echocardiographic outcomes at 1 year of follow-up.
Baseline CharacteristicsTable 1 Baseline Characteristics
Overall Population
(n  663)
Age, yrs 81.0 7.3
Female 371 (56.0)
Diabetes mellitus 175 (26.4)
Coronary artery disease 320 (48.3)
Prior acute pulmonary edema 213 (32.1)
Prior balloon valvuloplasty 113 (17.0)
Prior myocardial infarction 143 (21.6)
Prior stroke 48 (7.2)
Prior bypass graft surgery 104 (15.7)
Prior percutaneous coronary intervention 189 (28.5)
Peripheral vascular disease 127 (19.2)
Chronic obstructive pulmonary disease 141 (21.3)
Cirrhosis Child class A or B 13 (2.0)
Prior neoplasia 84 (12.7)
Renal insufficiency* 154 (23.2)
Atrial fibrillation 109 (16.4)
Prior pacemaker 42 (6.3)
Porcelain aorta 72 (10.9)
NYHA functional class III and IV 434 (71.5)
Logistic EuroSCORE, % 23.0 13.7
Baseline echocardiographic parameters
Left ventricular ejection fraction, % 52.1 25.5
Peak pressure gradient, mm Hg 83.7 25.2
Mean pressure gradient, mm Hg 51.8 17.0
Annulus diameter, mm 22.2 2.2
Aortic regurgitation 3 or 4 35 (5.3)Values are mean  SD or n (%). *Defined as serum creatinine 1.5 mg/dl. †Significant differences betw
NYHA  New York Heart Association; ViV  valve-in-valve.ethods
onsecutive patients (n  663)
ndergoing TAVI with the 18-F
RS at 14 centers across Italy
ere enrolled prospectively in a
edicated web-based database.
atient eligibility criteria, regis-
ry design, features of the third-
eneration CRS, and technical
etails of the procedure have
een described elsewhere (1,6).
nd point definitions. Proce-
ural success was defined as device deployment with fall of
ransaortic peak-to-peak gradient, without any periprocedural
ajor adverse cardiovascular and cerebrovascular event
MACCE) within 24 h of prosthesis implantation.
MACCE were defined as the composite of death resulting
rom any cause, myocardial infarction, stroke, or conversion to
pen heart surgery. Myocardial infarction was defined as
reatinine kinase-MB enzyme elevation 3 times the upper limit
f the normal value. Major access site complication was defined
s vascular rupture with fatal bleeding or need for urgent
ascular surgery or transcatheter repair. Major bleeding was
No ViV Group
(n  639)
ViV Group
(n  24) p Value
81.0 7.3 80.3 6.2 0.656
358 (56.0) 13 (54.1) 0.857
171 (26.7) 4 (16.6) 0.271
306 (47.9) 14 (58.3) 0.315
203 (31.8) 10 (41.7) 0.308
111 (17.4) 2 (8.3) 0.193
138 (21.6) 5 (20.9) 0.929
45 (7.0) 3 (12.5) 0.248
100 (15.6) 4 (16.7) 0.535
181 (28.3) 8 (33.3) 0.594
123 (19.2) 4 (16.7) 0.500
136 (21.3) 5 (20.8) 0.958
11 (1.7) 2 (8.3) 0.077
79 (12.4) 5 (20.8) 0.176
149 (23.3) 5 (20.8) 0.777
106 (16.6) 3 (12.5) 0.424
41 (6.4) 1 (4.2) 0.542
72 (11.3) 0 (0.0) 0.060
415 (64.9) 19 (79.2) 0.486
22.9 13.7 23.6 14.3 0.803
52.2 25.9 49.3 15.1 0.581
83.9 25.2 79.0 22.4 0.359
52.0 17.1 45.4 14.8 0.062
22.1 2.1 23.6 2.7 0.010†
33 (5.1) 2 (8.3) 0.365
Abbreviations
and Acronyms
CRS  CoreValve
ReValving System
MACCE  major adverse
cardiovascular and
cerebrovascular event(s)
PPL  paraprosthetic leak
TAVI  transcatheter aortic
valve implantation
ViV  valve-in-valveeen patients who underwent standard procedure and those who underwent 2-valve implantation.
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more of packed red blood cells.
Statistical analysis. Continuous variables are presented as
mean  SD and were compared with the use of the paired t
test or the Wilcoxon signed-rank test, as applicable. Categor-
ical variables are presented as counts and percentages and
compared with the use of the Fisher exact or chi-square test, as
appropriate. A 2-sided p value 0.05 was considered statisti-
cally significant. MACCE and mortality rates and actuarial
freedom from adverse events were estimated by using the
Kaplan-Meier method, and differences between the groups
were evaluated with the log-rank test. All data were processed
using the Statistical Package for Social Sciences version 18
(SPSS, Inc., Chicago, Illinois).
Results
A total of 663 patients (mean age, 81.0  7.3 years; mean
logistic EuroSCORE, 23.0  13.7%) who underwent TAVI
ere included in this analysis. No statistically significant
ifference was observed in terms of baseline clinical character-
stics between patients who underwent the standard procedure
non-ViV group) and those requiring an additional prosthesis
ith the ViV technique (ViV group) (Table 1). The mean
nnulus diameter measured by transthoracic echocardiogram
r transesophageal echocardiogram was larger in the ViV
roup (22.1  2.12 mm vs. 23.6  2.7 mm; p  0.010).
ransfemoral access was the preferred route for implantation
sed in a large majority of patients (n  599; 90.3%).
Procedural OutcomesTable 2 Procedural Outcomes
Overall Population
(n  663)
Procedural variables, min
Procedure time 79.1 33.6
Fluoroscopy time 21.3 13.3
Approach
Transfemoral 599 (90.3)
Transsubclavian 64 (9.7)
Device†
CRS 26 mm 394 (59.4)
CRS 29 mm 269 (40.6)
Ratio CRS diameter/aortic annulus‡ 1.23 0.1
Post dilation 68 (10.2)
Procedural success 650 (98.0)
Valve embolization 4 (0.6)
Death 6 (0.9)
Myocardial infarction 0 (0)
Stroke 8 (1.2)
Conversion to open heart surgery 5 (0.8)
MACCE 18 (2.7)
Major access site complications 13 (2.0)
Cardiac tamponade 8 (1.2)
Values are mean  SD or n (%). *Significant differences between patients who underwent standa
‡Aortic annulus measured by transthoracic echocardiogram.
CRS  CoreValve Revalving System; MACCE  major adverse cardiovascular and cerebrovascular evenubclavian access was used as an alternative in cases with
nfavorable ileofemoral anatomic characteristics (n  54;
.1%). Implantation of the 26-mm CRS prosthesis was more
requent (n  394; 59.4%) than implantation of the 29-mm
evice (n  269; 40.9%).
rocedural outcomes. In the following paragraph, presen-
ation style for parameter results is XX/XX/XX for overall/
on-ViV/ViV groups (p value for non-ViV group vs. ViV
roup). Procedural outcomes are reported in Table 2. The ViV
echnique was associated with longer procedural time (p 
.001) and fluoroscopy time (p  0.001).
Overall procedural success rate was high: 98%/97.9%/100%
p  0.616). Intraprocedural mortality (0.9%/0.9%/0%; p 
.801) and MACCE (2.7%/2.8%/0%; p 0.510) were similar
n all groups. No significant differences were observed in the
reatment groups in the occurrence of other important com-
lications such as major access site complications (2.0%/3.7%/
.2%; p  0.348) or cardiac tamponade (1.2%/1.2%/0%; p 
.743).
Prosthesis underexpansion was managed in all cases with
ost-implant balloon dilation, whereas prosthesis migration
ccurred in 4 cases and was managed successfully with implan-
ation of 2 (in-series) Corevalve prostheses (Medtronic, Inc.)
n  2), 1 conversion to surgery, and 1 balloon aortic
alvuloplasty.
Of all the patients in ViV group (n 24), the 26-mm CRS
as implanted as the primary device in 15 patients (62.4%) and
he larger 29-mm prosthesis was implanted in 9 patients
No ViV Group
(n  639)
ViV Group
(n  24) p Value
78.0 33.4 101.3 30.8 0.001*
20.6 12.2 35.9 25.5 0.001*
0.306
576 (90.1) 23 (90.4)
63 (9.9) 1 (9.6)
0.898
379 (59.3) 15 (62.5)
260 (40.7) 9 (37.5)
1.23 0.1 1.21 0.9 0.397
56 (8.8) 12 (50) 0.001*
626 (97.9) 24 (100) 0.616
4 (0.6) 0 (0.0) 0.831
6 (0.9) 0 (0.0) 0.801
0 (0) 0 (0.0) 1.000
8 (1.2) 0 (0.0) 0.743
5 (0.8) 0 (0.0) 0.831
18 (2.8) 0 (0.0) 0.510
12 (3.7) 1 (4.2) 0.384
8 (1.2) 0 (0.0) 0.743
edure and those who underwent 2-valve implantation. †Refers to the first prosthesis implanted.rd proct(s); ViV  valve-in-valve.
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significant PPL was characterized by lower deployment inside
the left ventricle in 75.0% (n  18) (Fig. 1) and by higher
deployment above the annulus level in 25.0% (n 6) (Fig. 2).
In 13 patients (54.1%), a balloon dilation was performed to
optimize device expansion after implantation.
There were no reports of impingement or jailing of coronary
ostia or damage to structures in the aortic root and mitral valve
after deployment of the second device. No significant gradient
was measured across the 2 CRS devices in any patient in the
ViV group.
Clinical and echocardiographic outcomes. The median
follow-up duration for the entire population was 10.5 months
(interquartile range: 6.5 to 16.7 months). Overall 30-day
mortality was 5.4%; 30-day mortality was 5.6% in the non-ViV
group and 0% in the ViV group (p  0.238). Mortality
remained relatively low and statistically similar in both groups
at the 12-month follow-up (13.7% vs. 4.5%, respectively; p 
0.230). No significant difference in the rate of MACCE
(14.1% vs. 4.5%; p  0.158) was observed between groups at
both follow-up intervals. Incidence of all-cause mortality and
Figure 1 Example of Low Implantation of CoreValve ReValving
The dotted line indicates the sinuses of Valsalva contour, the upper white line designMACCE are reported in Figures 3 and 4. New York Heart eAssociation functional class III/IV at discharge was virtually
absent in both groups (2.0% vs. 0%; p  0.446). This benefit
was sustained at 30 days (5.6% vs. 0%; p  0.890) and 1 year
(4.7% vs. 4.1%; p  0.671). A higher incidence of definitive
pacemaker implantation in the ViV group was reported at 30
days (14.4% vs. 33.3%; p  0.020).
At 12 months, no differences were noted between 2 groups
in terms of echocardiographic outcomes (mean transaortic
gradient, 10.1  4.2 vs. 10.5  5.2; p  0.838). No cases of
entral aortic regurgitation were observed. PPL of 2 or more
as observed in 26 (11.7%) and 1 (4.2%) patients in the
on-ViV and ViV groups, respectively (p  0.675). There
ere no instances of structural valve deterioration, valve throm-
osis, new PPL, cases of impairment of anterior mitral leaflet
n case of low deployment or thromboembolic events in any
atient in the ViV group.
iscussion
AVI is a challenging procedure that is associated with a
ignificant learning curve. Procedural success is 90% in
m Device Causing Severe Paraprosthetic Leak
e aortic annulus level, and the lower white line indicates the distal part of the frame.Syste
ates thxperienced centers (1,2). It is essential for operators to develop
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tion laboratory, trying to avoid bailout cardiac surgery, because
commercially available devices are extremely limited in their
ability for repositioning after initial deployment (4,5).
Several percutaneous bailout strategies have been developed
to address failed implantation, but few attempts have been
made to estimate the frequency and to discuss the follow-up
outcomes of these procedural issues (4). The ViV technique is
one of the most interesting interventional options to manage
device malposition that can occur during TAVI (4,5). To date,
the literature provides only a few anecdotal cases that demon-
strate the feasibility of this approach and show its midterm
effectiveness in isolated patients (5). In this study, we compared
acute and up to 12-month outcomes of patients undergoing
the standard procedure and those who had a second prosthesis
implanted inside the first one with the ViV technique as a
result of severe PPL.
A number of important messages emerge from this multi-
center registry. First, implantation of the CRS device was
performed with a very high success rate (98%) across different
centers, suggesting increasing operator familiarity and confi-
dence with the CRS device. The ViV technique was used in 24
Figure 2 Example of High Implantation of CRS Device Conditio
The dotted line indicates the sinuses of Valsalva contour, and the white line desipatients (3.6%); among them, 62.5% received a 26-mm CRSand 37.5% received a 29-mm CRS as their primary device. The
most common type of device malposition was deployment that
was too low inside the LVOT (75% of cases), whereas a higher
implantation relative to the aortic annulus occurred less fre-
quently. In more than one half of cases, balloon dilation was
necessary to optimize the expansion of the second device. This
was accomplished without any damage to the leaflets or aortic
root structures.
Second, the procedural, 30-day, and 12-month outcomes of
the ViV group are not different from the outcomes of those
who underwent the uneventful procedure. Procedural success
was obtained in 100% of the ViV patients, with no periproce-
dural death. Overall survival as well as freedom from MACCE
at 1 and 12 months were not statistically different between the
2 groups, with high 12-month survival (86.3% vs. 95.5%,
non-VIV vs. ViV group, respectively). Midterm prosthesis
performances were good. No cases of valve deterioration or
new onset of central or perivalvular regurgitation were ob-
served. In addition, there were no reports of thrombotic or
embolic events in the ViV group, which reflects well on the
design features and the endothelialization of the CRS device.
The initial clinical and echocardiographic successes were main-
Severe PPL
the aortic annulus level. Abbreviations as in Figure 1.ning
gnatestained for up to 1 year in all patients.
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restriction of mitral valve leaflets in the ViV group. The
incidence of atrioventricular block requiring definitive pacing
was higher (33.3% vs. 14.5% in the non-ViV group; p 
0.020). This correlates with the fact that nearly 80% of patients
undergoing the ViV procedure had placement of the first
prosthesis that was too low into the left ventricle, which
exposed them to the risk of developing permanent conduction
disorders (7).
The demonstration of the effectiveness of the ViV technique
at midterm follow-up in a large number of cases performed at
different institutions has implications. The ViV technique can
be used readily in the catheterization laboratory as bailout
therapy for a failed implantation resulting from a malposi-
tioned valve with severe PPL when the attempt of reposition
with the snare technique fails, preventing conversion to emer-
gency open-heart surgery (5). The availability of a bailout
provides a margin of safety and enhances operator confidence.
This is important for a nascent technology like TAVI to gain
widespread clinical acceptance.
However, 2 main potential concerns associated with this
technique still remain. It is unknown whether the presence of
2 valves could impact on the long-term durability of the
prosthesis, and the feasibility of cannulating the coronary ostia
Figure 3 Time-to-Event Curves for the Mortality End Point
Event rates were calculated with the use of Kaplan-Meier methods
and were compared with the use of the log-rank test. ViV  valve-in-valve.after the ViV procedure needs to be carefully assessed.Conclusions
This analysis from the Italian CoreValve Registry demon-
strates that the ViV technique is an effective percutaneous
approach that may be accomplished with encouraging acute
and midterm outcomes when severe PPL occurs after TAVI.
This technique can be performed safely as a bailout procedure
to avoid surgical conversion. Larger series and longer follow-up
are warranted to determine the safety, efficacy, and durability of
this technique.
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